We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

78 hedge funds and large institutions have $50.5M invested in Cue Biopharma in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

428% more call options, than puts

Call options by funds: $586K | Put options by funds: $111K

156% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 9

123% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 13

24% more funds holding

Funds holding: 63 → 78 (+15)

17% more capital invested

Capital invested by funds: $43M → $50.5M (+$7.51M)

0.14% more ownership

Funds ownership: 0.93% → 1.07% (+0.14%)

Holders
78
Holders Change
+15
Holders Change %
+23.81%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
23
Reduced
9
Closed
13
Calls
$586K
Puts
$111K
Net Calls
+$475K
Net Calls Change
+$371K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$5.49M
2
State Street
State Street
Massachusetts
+$2M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.55M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.08M
5
Northern Trust
Northern Trust
Illinois
+$992K

Top Sellers

Rank Fund Capital Flow
1
PM
Prosight Management
Texas
-$4.11M
2
Millennium Management
Millennium Management
New York
-$653K
3
PAWC
P.A.W. Capital
Connecticut
-$536K
4
CC
Carlson Capital
Texas
-$470K
5
VC
Voss Capital
Texas
-$446K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
51
American International Group
New York
$60.7K +$65.2K +555 New
VOYA Investment Management
52
VOYA Investment Management
Georgia
$53.1K +$57K +485 New
Two Sigma Investments
53
Two Sigma Investments
New York
$51.4K +$55.1K +469 New
SWM
54
SeaCrest Wealth Management
New York
$51.1K – – –
AG
55
Algert Global
California
$48K +$51.8K +441 New
Barclays
56
Barclays
United Kingdom
$47.3K +$27.1K +231 +115%
American Century Companies
57
American Century Companies
Missouri
$44K +$47.2K +402 New
California State Teachers Retirement System (CalSTRS)
58
California State Teachers Retirement System (CalSTRS)
California
$42K +$45K +383 New
LPL Financial
59
LPL Financial
California
$38.6K – – –
Citigroup
60
Citigroup
New York
$37.6K +$40.3K +343 New
BPA
61
Beacon Pointe Advisors
California
$36.5K – – –
BNP Paribas Financial Markets
62
BNP Paribas Financial Markets
France
$33.2K +$35.3K +300 +10,000%
GG
63
Gleason Group
Kentucky
$21.9K +$23.5K +200 New
AB
64
Amalgamated Bank
New York
$19K +$20.6K +175 New
NFSG
65
Newbridge Financial Services Group
Florida
$18.3K – – –
Fidelity Investments
66
Fidelity Investments
Massachusetts
$17.9K +$1.76K +15 +10%
Legal & General Group
67
Legal & General Group
United Kingdom
$15.4K +$16.5K +140 New
AIP
68
Ameritas Investment Partners
Nebraska
$10.4K +$11.2K +95 New
TRCT
69
Tower Research Capital (TRC)
New York
$10.3K +$11K +94 New
Royal Bank of Canada
70
Royal Bank of Canada
Ontario, Canada
$8K +$8.46K +72 New
MLICM
71
Metropolitan Life Insurance Company (MetLife)
New York
$7K +$7.52K +64 New
BHWM
72
Beaird Harris Wealth Management
Texas
$2.91K – – –
KFS
73
Kelly Financial Services
Massachusetts
$1.82K – – –
Northwestern Mutual Wealth Management
74
Northwestern Mutual Wealth Management
Wisconsin
$1.82K +$2K +17 New
HI
75
Harbour Investments
Wisconsin
$1.6K – – –
1 2
3
4

CUE Hedge Fund Activity: Q2 2023 in Review

78 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q2 2023, worth a combined $50.5M — up 17% from $43M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new CUE positions and 13 closed out — a net gain of 16 holders — while 23 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, adding an estimated $5.49M. The largest seller was Prosight Management, exiting entirely with an estimated $4.11M sold.

  • 78 institutional investors held Cue Biopharma (CUE) as of Q2 2023, up from 63 in Q1 2023.
  • Funds reported $50.5M of Cue Biopharma stock for Q2 2023, up 17% quarter-over-quarter.
  • 29 funds opened new Cue Biopharma positions in Q2 2023 and 13 closed out, a net change of +16 holders.
  • The largest Cue Biopharma buyer in Q2 2023 was BlackRock, an estimated $5.49M added.
  • The largest Cue Biopharma seller in Q2 2023 was Prosight Management, an estimated $4.11M sold.

Based on aggregated 13F filings for Q2 2023.